Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612477 | 0.84 | LMNA (0.41) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL8104294 | 0.84 | LMNA (0.41) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL5903747 | 0.83 | LMNA (0.40) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL27416424 | 0.80 | LMNA (0.38) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL8673536 | 0.79 | POLG (0.51) | POLBPOLA1POLG | |
| SCHEMBL7062916 | 0.79 | ALB (0.33) | ALB | |
| SCHEMBL30818468 | 0.78 | PDE3A (0.36) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL3038818 | 0.77 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL5940639 | 0.77 | PDE3A (0.44) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL30612741 | 0.77 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNACACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20130303479-A1 | Antiretroviral Cyclonucleoside Compositions and Methods and Articles of Title of Invention Manufacture Therewith | HAWLEY TODD WILLIAM (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012100017-A2 | ANTIRETROVIRAL CYCLONUCLEOSIDE COMPOSITIONS AND METHODS AND ARTICLES OF MANUFACTURE THEREWITH | LENTX, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008118879-A2 | ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | PNP, TYMP, MTAP | PDE3A 948/4885PDE4D 1162/4885SLC29A1 82/4885 |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | CYP11B1, CYP51A1, CYP11B2 | PDE3A 461/4885PDE4D 1570/4885SLC29A1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.